

October 2016

ODEP RATINGS AND PROCUREMENT ODEP STATEMENT

We have been approached by at least two implant manufacturers who have been having difficulties in organising contracts for the sale of their implants in various Trusts as the implant involved does not have a 10A rating.*

We have been informed that the purchasers have quoted the document below entitled "Value Added Clinical Commissioning Policies". It only refers to total hip and hip resurfacing, there is no mention of knees.

The statement below is available to manufacturers to use as they wish.

Several orthopaedic manufacturers of total joint replacements have contacted ODEP for ODEP's view on the policy outlined in the section on Hip Prostheses and Resurfacing in the CCG's document "Value Based Clinical Commissioning Policies"

Version 3
Review: December 2015
Implementation: April 2016

Value Based Clinical Commissioning Policies

Hip Prostheses and Resurfacing

Policy: Prostheses for total hip replacement and resurfacing arthroplasty will only be funded in accordance with the criteria specified below:

- The prosthesis used has a rate (or projected rate) of revision of 5% or less at 10 years (ODEP 10A* rating, or A* rating at less than 10 years)

ODEP considers these policies are entirely consistent with their philosophy.

ODEP expects most manufacturers to eventually achieve a 10A* rating for the hip replacements they are marketing in the NHS.


Whilst achieving this rating they will submit data to sequentially achieve ratings at "Pre-Entry", 3, 5 and 7 years by submitting data with a failure rate less than 3% at 3 years, 5% at 5, 7 and 10 years.

NICE and ODEP agree that any benchmarking system, used in the UK, should not be designed to restrict the use of implants with less than 10 years of data but the performance of all implants, with less than 10 years of data, should be scrutinised at proscribed time points. Neither NICE or ODEP are designed to frustrate development of newer and better prostheses.

ODEP is designed to effectively be a platform for a 10 year clinical trial of a hip replacement (including resurfacing arthroplasty) with manufacturers collecting data, under carefully defined rules, from multiple sources.

For more details about ODEP please go to www.odep.org.uk

Kind Regards



Keith Tucker FRCS
Consultant Orthopaedic Surgeon Norwich
Chair of ODEP and the Beyond Compliance Advisory Group
Past President British Hip Society